In response, specific tyrosine kinase inhibitors have been developed to selectively inhibit the activity of the BCR-ABL1 tyrosine kinase domain, thereby improving clinical outcomes and prognosis for patients with chronic myeloid leukemia (CML) (Hou et al., 2021; Kantarjian et al., 2021; Lin et al., 2020). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.